[1]江茂情,吴华.18F-FDG和18F-FLT PET-CT在肿瘤非手术治疗早期疗效评价中的应用[J].国际放射医学核医学杂志,2012,36(6):339-343.[doi:10.3760/cma.j.issn.1673-4114.2012.06.005]
　JIANG Mao-qing,WU Hua.18F-FDG and 18F-FLT PET-CT in evaluation of the early response of malignant tumors after different therapies[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(6):339-343.[doi:10.3760/cma.j.issn.1673-4114.2012.06.005]
点击复制

18F-FDG和18F-FLT PET-CT在肿瘤非手术治疗早期疗效评价中的应用(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
36
期数:
2012年第6期
页码:
339-343
栏目:
PET-CT临床应用及新进展(重点专题)
出版日期:
1900-01-01

文章信息/Info

Title:
18F-FDG and 18F-FLT PET-CT in evaluation of the early response of malignant tumors after different therapies
作者:
江茂情;  吴华
福建省厦门市厦门大学附属第一医院核医学科闽南PET中心, 福建 361005
Author(s):
JIANG Mao-qing;  WU Hua
Department of Nuclear Medicine and Minnan PET Center, the First Affiliated Hospital of Xiamen University, Xiamen 361005, China
关键词:
肿瘤; 氟脱氧葡萄糖F18; 氟胸腺嘧啶F18; 正电子发射断层显像术; 疗效
Keywords:
Neoplasms; Fluorodeoxyglucose F18; Fluorothymidine F18; Positron emission tomography; Response
DOI:
10.3760/cma.j.issn.1673-4114.2012.06.005
摘要:
早期监测肿瘤在不同治疗方法中的疗效已成为临床上亟待解决的问题。PET可从分子水平上观察细胞生物学行为,尤其是对肿瘤的早期诊断、分期及疗效评价具有较高的特异度。18F-FDG为葡萄糖类代谢显像剂,作为目前应用最为广泛的显像剂,因其本身固有的一些特点表现为对肿瘤的非特异性显像。3’-脱氧-3’-18F-氟胸腺嘧啶(18F-FLT)为核苷酸类代谢显像剂,在细胞增殖显像方面的应用较为广泛。两者在肿瘤监测、分期及疗效评价方面各具特点。该文就PET-CT在肿瘤疗效评价中的应用进行综述,同时探讨两者在监测非手术治疗疗效时何者更具有优势。
Abstract:
For the evaluation of the early effect of different therapies for the treatment of malignant tumors, reduction in tumor volume is the most commonly used criterion for efficacy. However, the time until tumor shrinkage can be long and it requires repeated tumor volume measurements several times weekly to show effect. Non-invasive method such as PET allows for biological processes to be visualized and quantified non-invasively over time, and it has a high specificity for the early diagnosis, staging and evaluate the response of tumors. 18F-FDG is the most widely used radiotracer for imaging in oncology and is very useful for detecting and characterizing cancers currently. But it is not a tumor specific agent for the intrinsic property. 3’-deoxy-3’-18F-fluorothymidine(18F-FLT) is used as a PET tracer for visualization of cell proliferation and it has become more widely used in clinic. Both of them have their own features in the diagnosis, staging and early detect response of tumors. This article reviewed the application of 18F-FDG and 18F-FLT to evaluate the early response of malignant tumors after different therapies. Besides, at the same time, 18F-FDG and 18F-FLT which is more specific or superiority to measure early response of tumors after definite treatment was discussed.

参考文献/References:

[1] Westerterp M,van Westreenen HL,Reitsma JB,et al.Esophageal cancer:CT,endoscopic US,and FDG PET for assessment of response to neoadjuvant therapy systematic review.Radiology,2005,236(3):841-851.
[2] 章斌,吴翼伟,王振欣,等.18F-FLTPET/CT显像在鼻咽癌诊断及分期中的应用.中华核医学杂志,2011,31(5):306-309.
[3] Debucquoy A,Devos E,Vermaelen P,et al.18F-FLT and 18F-FDG PET to measure response to radiotherapy combined with celecoxib in two colorectal xenograft models.Int J Hadiat Biol,2009,85(9):763-771.
[4] Wei LH,Su H,Hildebrandt IJ,et al.Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma.Clin Cancer Res,2008,14(11):3416-3426.
[5] Aide N,Kinross K,Cullinane C,et al.18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.J Nucl Med,2010,51(10):1559-1564.
[6] Ullrich RT,Zander T,Neumaier B,et al.Early detection of erlotinib treatment response in NSCLC by 3’-deoxy-3’-[F]-fluoro-L-thymidine([F] FLT)positron emission tomography(PET).PLoSOne,2008,3(12):e3908.
[7] Uddin MK,Reignier SG,Coulter T,et al.Syntheses and antiproliferative evaluation of oxyphenisatin derivatives.Bioorg Med Chem Lett,2007,17(10):2854-2857.
[8] Jensen MM,Erichsen KD,Björkling F,et al,Early detection of response to experimental chemotherapeutic Top216 with[18F]FLT and[18F]FDG PET in human ovary cancer xenografts in mice.PLoS One,2010,5(9):e12965.
[9] Rosenberg B,Vancamp L,Krigas T.Inhibition of cell division inEscherichia coli by electrolysis products from a platinum electrode.Nature,1965,205(4972):698-699.
[10] Leyton J,Latigo JR,Perumal M,et al.Early detection of tumor response to chemotherapy by 3’-deoxy-3’-[18F]fluorothymidine positron emission tomography:the effect of cisplatin on a fibrosarcoma tumor model in vivo.Cancer Res,2005,65(10):4202-4210.
[11] Guchelaar HJ,Hoekstra HJ,de Vries EG,et al.Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities.Br J Cancer,1992,65(6):898-902.
[12] Been LB,Suurmeijer AJ,Elsinga PH,et al.18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas.J Nucl Med,2007,48(3):367-372.
[13] van Westreenen HL,Heeren PA,Jager PL,et al.Pitfalls of positive findings in staging esophageal cancer with F-18-fluorodeoxyglucose positron emission tomography.Ann Surg Oncol,2003,10(9):1100-1105.
[14] Yue J,Chen L,Cabrera AR,et al.Measuring tumor cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma:a pilot clinical study.J Nucl Med,2010,51(4):528-534.
[15] Han D,Yu J,Yu Y,et al.Comparison of 18F-fluorothymidine and 18F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus.Int J Radiat Oncol Biol Phys,2010,76(4):1235-1241.
[16] Giammarile F,Billotey C,Lombard-Bohas C,et al.18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumors.Nucl Med Commun,2011,32(2):91-97.
[17] Been LB,Hoekstra HJ,Suurmeijer AJ,et al.[18F]FLT-PET and[18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer.Oral Oncol,2009,45(12):e211-215.
[18] Apisarnthanarax S,Alauddin MM,Mourtada F,et al.Early detection of chemoradioresponse in esophageal carcinoma by 3’-deoxy-3’-3H-fluorothymidine using preclinical tumor models.Clin Cancer Res,2006,12(15):4590-4597.
[19] Goldberg N,Kundel Y,Purim O,et al.Early prediction of histopathological response of rectal tumors after one week of preoperative radiochemotherapy using 18F-FDG PET-CT imaging.A prospective clinical study.Radiat Oncol,2012,7:124.
[20] Oyama N,Ponde DE,Dence C,et al.Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation.J Nucl Med,2004,45(3):519-525.
[21] Sugiyama M,Sakahara H,Sato K,et al.Evaluation of 3’-deoxy-3’-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice.J Nucl Med,2004,45(10):1754-1758.

相似文献/References:

[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
　He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
　Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
　Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[4]陈顺军,程兵.肿瘤细胞凋亡核素显像分子探针研究进展[J].国际放射医学核医学杂志,2016,40(2):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
　Chen Shunjun,Cheng Bing.Progress in molecular probes of radionuclide tumor apoptosis imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
[5]陈晓艳,张江虹,邵春林.STAT3与辐射敏感相关性的研究进展[J].国际放射医学核医学杂志,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
　Chen Xiaoyan,Jianghong,Shao Chunlin.Research progresses of correlation between STAT3 and radiosensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
[6]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
　You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[7]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
　Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[8]李菲,黄俊星,张俊.18F-FDG PET/CT在食管癌中的临床应用[J].国际放射医学核医学杂志,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
　Li Fei,Huang Junxing,Zhang Jun.The clinical application of 18F-FDG PET/CT in esophageal cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
[9]赵舒怡,储小飞,樊赛军.血清肿瘤标志物与肿瘤放疗疗效评估的研究进展[J].国际放射医学核医学杂志,2015,39(5):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
　zhao shuyi,chu xiaofei,fan saijun..progression of study on serum tumor markers in evaluation of tumor radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
[10]许靖,李肖红,秦永德,等.帕金森病脑部葡萄糖代谢和脑多巴胺转运体PET显像特点的临床研究[J].国际放射医学核医学杂志,2016,40(5):338.[doi:10.3760/cma.j.issn.1673-4114.2016.05.003]
　Xu Jing,Li Xiaohong,Qin Yongde,et al.Clinical study of brain glucose metabolism and brain dopamine transporter PET imaging in patients with Parkinson’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):338.[doi:10.3760/cma.j.issn.1673-4114.2016.05.003]
[11]刘春利,李毅红.18F-FDG PET/CT在原发灶不明的脑转移瘤中的诊断价值[J].国际放射医学核医学杂志,2013,37(2):92.[doi:10.3760/cma.j.issn.1673-4114.2013.02.008]
　LIU Chun-li,LI Yi-hong.The value of 18F-FDG PET/CT in diagnosing brain metastases from unknown primary tumor[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):92.[doi:10.3760/cma.j.issn.1673-4114.2013.02.008]
[12]王胜军,杨卫东,赵小虎,等.18F-FDG PET/CT诊断多发癌的价值[J].国际放射医学核医学杂志,2013,37(2):96.[doi:10.3760/cma.j.issn.1673-4114.2013.02.009]
　WANG Sheng-jun,YANG Wei-dong,ZHAO Xiao-hu,et al.Value of 18F-FDG PET/CT in the diagnosis of multiple primary malignant neoplasms[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):96.[doi:10.3760/cma.j.issn.1673-4114.2013.02.009]
[13]王玉婷,黄钢,蒋瑾,等.18F-FDG PET用于肿瘤治疗疗效评价的meta分析进展[J].国际放射医学核医学杂志,2012,36(6):334.[doi:10.3760/cma.j.issn.1673-4114.2012.06.004]
　WANG Yu-ting,HUANG Gang,JIANG Jin,et al.Tumor response monitoring by 18F-FDG PET: updated review of meta-analyses[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(6):334.[doi:10.3760/cma.j.issn.1673-4114.2012.06.004]
[14]江茂情,吴华.18F-FDG和18F-FLTPET对肿瘤放化疗疗效评价的实验研究[J].国际放射医学核医学杂志,2011,35(3):146.[doi:10.3760/cma.j.issn.1673-4114.2011.03.004]
　JIANG Mao-qing,WU Hua.The experimental study on 18F-FDG and 18F-FLT PET in assessing the outcome of cancer chemotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(6):146.[doi:10.3760/cma.j.issn.1673-4114.2011.03.004]
[15]周敏,魏秋霞,林俊杰,等.良恶性肿瘤18F-FDG符合线路显像的临床价值[J].国际放射医学核医学杂志,2011,35(5):279.[doi:10.3760/cma.j.issn.1673-4114.2011.05.006]
　ZHOU Min,WEI Qiu-xia,LIN Jun-jie,et al.18F-FDG coincidence imaging for the detection of benign and malignant neoplasm[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(6):279.[doi:10.3760/cma.j.issn.1673-4114.2011.05.006]
[16]张慧玮,赵军.18F-FDG代谢显像相关分子机制的研究进展[J].国际放射医学核医学杂志,2011,35(1):1.[doi:10.3760/cma.j.issn.1673-4114.2011.01.001]
　ZHANG Hui-wei,ZHAO Jun.Progress of molecular mechanism of 18F-FDG metabolism imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(6):1.[doi:10.3760/cma.j.issn.1673-4114.2011.01.001]
[17]李亚军,张慧娟.放射性核素标记胆碱与18F-FDG PET肿瘤显像的对比研究[J].国际放射医学核医学杂志,2010,34(6):348.[doi:10.3760/cma.j.issn.1673-4114,2010.06.007]
　LI Ya-jun,ZHANG Hui-juan.Comparison choline with 18F-FDG PET in various tumors imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(6):348.[doi:10.3760/cma.j.issn.1673-4114,2010.06.007]
[18]李红梅,冯珏,李晓东,等.18F-FLT对恶性肿瘤治疗效果的评估价值[J].国际放射医学核医学杂志,2009,33(3):136.[doi:10.3760/cma.j.issn.1673-4114.2009.03.003]
　LI Hong-mei,FENG Jue,LI Xiao-dong,et al.The value of 18F-fluorothymidine to monitor the therapeutic effect of malignant tumor[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(6):136.[doi:10.3760/cma.j.issn.1673-4114.2009.03.003]
[19]司宏伟,徐慧琴,岳峤,等.肿瘤组织乏氧与葡萄糖代谢[J].国际放射医学核医学杂志,2009,33(4):200.[doi:10.3760/cma.j.issn.1673-4114.2009.04.003]
　SI Hong-wei,XU Hui-qin,YUE Qiao,et al.Hypoxia and glycometabolism in cancer tissue[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(6):200.[doi:10.3760/cma.j.issn.1673-4114.2009.04.003]
[20]陈香,赵晋华.PET及PET-CT在监测肿瘤治疗效果中的价值[J].国际放射医学核医学杂志,2007,31(6):354.
　CHEN Xiang,ZHAO Jin-hua.Value of PET and PET-CT for monitoring tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(6):354.

备注/Memo

备注/Memo:
收稿日期:2012-08-20。
基金项目:福建省自然科学基金重点项目(2008-59-11);厦门市科技计划指导性项目(3502720077056)
通讯作者:吴华(Email:wuhual025@163.com)
更新日期/Last Update: 1900-01-01